JPMorgan Downgrades Enanta Pharmaceuticals (ENTA) to Neutral

February 8, 2018 4:40 AM

JPMorgan downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Overweight to Neutral with a price target of $95.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found